Montag A & Associates Inc. reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 143,680 shares of the company’s stock after selling 6,323 shares during the period. Montag A & Associates Inc.’s holdings in Merck & Co., Inc. were worth $12,171,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC boosted its holdings in shares of Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after purchasing an additional 216 shares in the last quarter. Kilter Group LLC purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Bare Financial Services Inc raised its holdings in shares of Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after buying an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC lifted its position in Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after buying an additional 266 shares during the last quarter. Finally, Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. in the second quarter worth approximately $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Co., Inc. News Summary
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Multiple Phase 3 wins for KEYTRUDA combination therapies and subsequent U.S./EU regulatory activity strengthen Merck’s oncology franchise and support continued revenue growth from its biggest drug. Merck Keytruda Combos Strengthen Oncology Platform And Raise Patent Questions
- Positive Sentiment: KEYTRUDA remains the primary revenue driver (roughly half of pharma sales); strong 2025 sales momentum underpins near-term earnings expectations and helps explain why analysts still see upside despite recent gains. Merck’s Keytruda Drives its 2025 Revenue Surge: What’s Ahead?
- Positive Sentiment: Strategic collaboration with AI firm Tempus aims to accelerate AI-driven precision medicine — a potential long-term revenue/efficiency positive that signals Merck investing in data/AI capabilities across drug development and commercialization. AI-Powered Tempus Inks New Multi-Year Merck Deal
- Positive Sentiment: Value-oriented coverage highlights Merck as potentially undervalued despite a strong run — analysts point to modest upside, solid dividends and strategic reorganizations to offset Keytruda patent loss risk. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works
- Neutral Sentiment: Management presentation transcript from the TD Cowen healthcare conference provides detailed commentary on pipeline, strategy and financial outlook — useful for longer-term thesis but no single market-moving disclosure was highlighted. Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Negative Sentiment: Shares have pulled back amid short-term profit-taking and market-wide rotation; coverage noting a recent dip may amplify selling even as fundamentals remain solid. Merck (MRK) Stock Dips While Market Gains: Key Facts
Wall Street Analyst Weigh In
View Our Latest Analysis on Merck & Co., Inc.
Merck & Co., Inc. Price Performance
Shares of Merck & Co., Inc. stock opened at $119.67 on Wednesday. The firm has a market cap of $295.87 billion, a PE ratio of 16.44, a price-to-earnings-growth ratio of 2.33 and a beta of 0.27. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The company’s fifty day simple moving average is $113.56 and its two-hundred day simple moving average is $98.01.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.
Merck & Co., Inc. Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.
Insiders Place Their Bets
In related news, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the completion of the transaction, the chief marketing officer owned 70,615 shares in the company, valued at $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. Insiders own 0.09% of the company’s stock.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Further Reading
- Five stocks we like better than Merck & Co., Inc.
- New Copper-Rich “Kraken” Zone Discovered
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
